Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes
Susanna P.C. Höppener(Wilhelmina Children's Hospital), Marc H.A. Jansen(Radboud University Nijmegen), Saskia Haitjema(University Medical Center Utrecht), Mark de Groot(Utrecht University), Jaap Jan Boelens(Wilhelmina Children's Hospital), Julia Drylewicz(Inserm), Annet van Royen‐Kerkhof(Wilhelmina Children's Hospital), Saskia R Veldkamp(University of Amsterdam), Caroline A. Lindemans(University Medical Center Utrecht), Joris M. van Montfrans(Wilhelmina Children's Hospital)
Cited by 2
Related Papers
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
|The Lancet|2012|376
Consensus-based recommendations for the management of juvenile dermatomyositis
|Annals of the Rheumatic Diseases|2016|312